New hope for kidney patients: experimental drug AP1189 enters trial
NCT ID NCT04456816
First seen Mar 07, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This study tests an experimental drug called AP1189 in people with a rare kidney condition called idiopathic membranous nephropathy that causes severe protein leakage in urine. About 23 adults will receive either AP1189 or a placebo for 12 weeks, on top of their usual blood pressure medications. The main goals are to check the drug's safety and whether it reduces protein in the urine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME DUE TO IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus Universitetshospital
RECRUITINGAarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.